Lipocine Inc (LPCN) - Total Assets
Based on the latest financial reports, Lipocine Inc (LPCN) holds total assets worth $25.36 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check LPCN cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Lipocine Inc - Total Assets Trend (2011–2025)
This chart illustrates how Lipocine Inc's total assets have evolved over time, based on quarterly financial data. Explore LPCN long-term investment intensity to see how much of total assets are deployed in long-term investments.
Lipocine Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Lipocine Inc's total assets of $25.36 Million consist of 99.3% current assets and 0.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 30.6% |
| Accounts Receivable | $14.19K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Lipocine Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Lipocine Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lipocine Inc's current assets represent 99.3% of total assets in 2025, a decrease from 100.0% in 2011.
- Cash Position: Cash and equivalents constituted 30.6% of total assets in 2025, down from 70.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Lipocine Inc Competitors by Total Assets
Key competitors of Lipocine Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Lipocine Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.99 | 15.64 | 5.35 |
| Quick Ratio | 9.99 | 15.64 | 5.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $22.72 Million | $19.03 Million | $38.35 Million |
Lipocine Inc - Advanced Valuation Insights
This section examines the relationship between Lipocine Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.86 |
| Latest Market Cap to Assets Ratio | 1.12 |
| Asset Growth Rate (YoY) | -24.5% |
| Total Assets | $17.01 Million |
| Market Capitalization | $19.13 Million USD |
Valuation Analysis
Above Book Valuation: The market values Lipocine Inc's assets above their book value (1.12x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Lipocine Inc's assets decreased by 24.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lipocine Inc (2011–2025)
The table below shows the annual total assets of Lipocine Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $17.01 Million | -24.45% |
| 2024-12-31 | $22.51 Million | -2.13% |
| 2023-12-31 | $23.00 Million | -38.73% |
| 2022-12-31 | $37.54 Million | -28.47% |
| 2021-12-31 | $52.48 Million | +107.01% |
| 2020-12-31 | $25.35 Million | +28.97% |
| 2019-12-31 | $19.66 Million | -5.72% |
| 2018-12-31 | $20.85 Million | -17.66% |
| 2017-12-31 | $25.33 Million | -7.38% |
| 2016-12-31 | $27.34 Million | -39.74% |
| 2015-12-31 | $45.38 Million | +62.10% |
| 2014-12-31 | $27.99 Million | -39.29% |
| 2013-12-31 | $46.11 Million | +7990805.03% |
| 2012-12-31 | $577.00 | -98.22% |
| 2011-12-31 | $32.44K | -- |
About Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1… Read more